May 08, 2025

FDA Warns Physicians of Tianeptine Dangers

The FDA warns physicians about unapproved tianeptine products that are linked to severe adverse events, including dependence, toxicity, and death.

Conexiant

May 07, 2025

Cystic Fibrosis: New Evidence-Based Guidelines for Newborn Screening

New Cystic Fibrosis Foundation guidelines aim to improve consistency, equity, and accuracy in CF newborn screening nationwide.

Conexiant

May 05, 2025

FDA Monthly Round-up: Key April Updates

April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.

Conexiant

April 30, 2025

Childhood Wheeze May Be Tied to Ozone Levels

Early-life ozone exposure was linked to increased odds of asthma and wheeze in children aged 4 to 6 years.

Conexiant

April 30, 2025

New Phase III Data on Brensocatib Therapy

Phase III trial results show that once-daily brensocatib reduces pulmonary exacerbations and slows lung function decline in patients with bronchiectasis.

Conexiant

April 29, 2025

Foley Catheter Management: New Best Practices, Pitfalls

Foley catheter use is associated with a wide range of complications, from infections to urethral erosion.

Conexiant

April 29, 2025

Flu Shots Linked to Temporary Menstrual Changes

Study shows small, temporary cycle length increases after vaccination

Conexiant

April 28, 2025

Most Long COVID Cases Persist Beyond 2 Years

In a three-year follow-up study, fewer than 2% of long COVID cases reported resolution of symptoms, with vaccinated patients demonstrating significantly better physical and mental health outcomes.

Conexiant

April 25, 2025

FDA Approves Penpulimab-kcqx for NPC

The FDA approved penpulimab-kcqx for first line and previously treated recurrent or metastatic non-keratinizing nasopharyngeal carcinoma.

Conexiant